[
  {
    "ts": null,
    "headline": "Biogen : to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference",
    "summary": "Cambridge, MA, - - Biogen Inc. announced today that Robin Kramer, Chief Financial Officer, will participate in a fireside chat during the Goldman Sachs 46th Annual Global Healthcare Conference. The...",
    "url": "https://finnhub.io/api/news?id=8f277ff4a23eb1a9d0a073121fe3f8808f7909282b7e596f16af16b15f12e51c",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748972045,
      "headline": "Biogen : to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference",
      "id": 134996811,
      "image": "",
      "related": "BIIB",
      "source": "Finnhub",
      "summary": "Cambridge, MA, - - Biogen Inc. announced today that Robin Kramer, Chief Financial Officer, will participate in a fireside chat during the Goldman Sachs 46th Annual Global Healthcare Conference. The...",
      "url": "https://finnhub.io/api/news?id=8f277ff4a23eb1a9d0a073121fe3f8808f7909282b7e596f16af16b15f12e51c"
    }
  },
  {
    "ts": null,
    "headline": "Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors",
    "summary": "Maha Radhakrishnan, MD Maha Radhakrishnan, MD BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. “We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan’s deep and meaningful experience in global drug development will be inv",
    "url": "https://finnhub.io/api/news?id=ffbbd1d9d0ee42f7282b6240d93b09824516bf8fc1547da4f1cdfa8aeebce746",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748948400,
      "headline": "Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors",
      "id": 134976116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Maha Radhakrishnan, MD Maha Radhakrishnan, MD BOSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. “We are pleased to have Dr. Radhakrishnan join the Board at this time of tremendous clinical momentum at Entrada, led by the continued advancement of our Duchenne muscular dystrophy franchise. Dr. Radhakrishnan’s deep and meaningful experience in global drug development will be inv",
      "url": "https://finnhub.io/api/news?id=ffbbd1d9d0ee42f7282b6240d93b09824516bf8fc1547da4f1cdfa8aeebce746"
    }
  },
  {
    "ts": null,
    "headline": "abrdn World Healthcare Fund Q1 2025 Commentary",
    "summary": "The equity portion of the Fund rose (gross of fees) but underperformed its benchmark over the quarter.",
    "url": "https://finnhub.io/api/news?id=38a3fa6a8cead9c9e75f77bfc020116de74993e8dc05a0e0b75137cad50c9df0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748938800,
      "headline": "abrdn World Healthcare Fund Q1 2025 Commentary",
      "id": 134976414,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/91598774/image_91598774.jpg?io=getty-c-w1536",
      "related": "BIIB",
      "source": "SeekingAlpha",
      "summary": "The equity portion of the Fund rose (gross of fees) but underperformed its benchmark over the quarter.",
      "url": "https://finnhub.io/api/news?id=38a3fa6a8cead9c9e75f77bfc020116de74993e8dc05a0e0b75137cad50c9df0"
    }
  }
]